Home » Newsletters » BioWorld Science

BioWorld Science

July 1, 2008

View Archived Issues

Duloxetine effective in reducing osteoarthritis knee pain

Exelixis and GSK to conclude 6-year collaboration as scheduled in October 2008

FDA approves Metvixia and aktilite CL-128 for actinic keratosis

Three-month safety and efficacy data reported for Medidur FA

Snapshots: New data on lenalidomide development

Preclinical results support accelerated development of iCo-009

Canadian clearance for phase II study of TLN-232 in metastatic melanoma

NIH awards phase II SBIR grant to Pressure BioSciences to develop PCT

Schering-Plough and Merck withdraw loratadine/montelukast NDA and terminate joint venture

Dako enters collaboration with Bristol-Myers for pharmacodiagnostic tests for cancer patients

Greer completes enrollment in phase III clinical trial of SLIT for short ragweed allergies

Action starts phase II trial with AP-214 for organ failure associated with surgery

Affymax initiates enrollment in phase II Hematide trial

New agents for periodontitis imparted in recent patent

Recent sanofi-aventis patent discloses novel antithrombotic agents

Recent patents describe novel antidiabetic agents

Catalyst commences enrollment for U.S. phase II CPP-109 trial in addiction

Centocor submits BLA to FDA requesting approval of golimumab

A novel ACE2 activator shows benefit in experimental pulmonary hypertension

Novexel discontinues development of antibiotic NXL-101

Peregrine doses first patient in phase II bavituximab trial in NSCLC

RP-193, a novel CFTR activator enhances chloride secretion in vitro

Takeda submits NDA in Japan for panitumumab

Cytokinetics reports promising data for ispinesib in combination with capecitabine

Neuren to finish phase III Glypromate trial 6 months ahead of schedule

Intellect and MRC Technology achieve milestone in Alzheimer's therapeutic antibody program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...